1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,260 | 1,450 | 08:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE I CLINICAL TRIAL OF IMC-003/IMM72 | 3 | HKEx | ||
| 12.08. | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | - | HKEx | ||
| 31.07. | Instil Bio: ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China | 78 | GlobeNewswire (Europe) | Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting... ► Artikel lesen | |
| 30.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - MILESTONE PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH AXION BIO | - | HKEx | ||
| 11.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS | 2 | HKEx | ||
| 02.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - CLEARANCE OF IND APPLICATION FOR IMM2510/AXN-2510 BY THE U.S. FDA | 1 | HKEx | ||
| 30.06. | IMMUNEONCO-B (01541): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | - | HKEx | ||
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 30.06. | IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.06. | IMMUNEONCO-B (01541): CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE | - | HKEx | ||
| 23.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR THE CLINICAL TRIAL OF IMC-003/IMM72 | 4 | HKEx | ||
| 16.06. | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| 09.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER | 1 | HKEx | ||
| 28.05. | IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 3 | HKEx | ||
| 28.05. | IMMUNEONCO-B (01541): I. POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2025; II. APPOINTMENT OF DIRECTOR | - | HKEx | ||
| 27.05. | IMMUNEONCO-B (01541): SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | 2 | HKEx | ||
| 23.05. | Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago | 1 | GlobeNewswire (USA) | ||
| 22.05. | Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 ... | 274 | GlobeNewswire (Europe) | Phase 3 trial of '2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions Monotherapy US dose optimization Phase 1b/2... ► Artikel lesen | |
| 22.05. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIALS OF IMM2510/AXN-2510 IN COMBINATION WITH CHEMOTHERAPY IN FIRST-LINE NSCLC | - | HKEx | ||
| 14.05. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 14.05. | IMMUNEONCO-B (01541): INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 71,77 | +0,36 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| QIAGEN | 42,580 | +0,69 % | Qiagen: Feedback zur Roadshow | Qiagen-CFO Roland Sackers hat in Frankfurt eine Roadshow durchgeführt. Im Fokus der Investoren standen dabei die Wachstumstreiber von Qiagen. Es ging auch um die derzeitigen operativen Herausforderungen... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,290 | +1,80 % | SUSANNAH CONSTANTINE, 63, CHOOSES THE NEW ALMA HARMONY BIO-BOOST FOR MID-LIFE SKIN CONFIDENCE | *The Next Generation Collagen Laser Facial for glowing, smoother, firmer skin*
The author, podcaster and TV personality Susannah Constantine, 63, opens up about confidence, ageing, and... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 42,590 | +0,54 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update | Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial... ► Artikel lesen | |
| EVOTEC | 6,116 | +0,59 % | Evotec-Aktie: Neue Tiefs in Sicht? Nur ein Wunder kann jetzt wohl noch helfen! | © Foto: Foto von Anna Shvets auf PexelsDie Hamburger Biotechfirma Evotec kämpft ums Überleben. Das traditionelle Geschäft mit der Wirkstoffforschung bricht weg, während die hochgelobte Biologics-Sparte... ► Artikel lesen | |
| THARIMMUNE | 4,970 | 0,00 % | Tharimmune Inc.: Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments | RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 56,56 | +2,08 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,000 | -3,50 % | Piper Sandler nimmt Coverage für Janux Therapeutics mit "Overweight"-Rating auf | ||
| BIONTECH | 95,10 | +0,79 % | Warten auf den Durchbruch: Steht die Mega-Rallye bei der BioNTech-Aktie kurz bevor? | Investoren warten bei BioNTech auf neue Produkte. Einen aussichtsreichen Kandidaten hat der Biotechkonzern. Eine Milliardenkooperation ist bereits geschlossen. Zudem ist die Kasse gut gefüllt Seit Frühjahr... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 14,610 | -5,62 % | Jefferies belässt Mineralys auf 'Hold' und blickt auf entscheidende Daten von AstraZeneca | ||
| RECURSION PHARMACEUTICALS | 4,765 | 0,00 % | Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares | ||
| VERA THERAPEUTICS | 22,605 | +2,29 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,640 | +0,68 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BEAM THERAPEUTICS | 15,990 | 0,00 % | Cantor Fitzgerald reiterates Overweight rating on Beam Therapeutics stock | ||
| BICARA THERAPEUTICS | 11,630 | +6,11 % | Piper Sandler initiates Bicara Therapeutics stock with Overweight rating |
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.